📢 Product Launch Announcement: Tafhep 25
We are proud to introduce Tafhep 25, a next-generation antiviral therapy containing Tenofovir Alafenamide 25 mg, designed specifically for the management of chronic hepatitis B infection.
Tafhep 25 offers potent viral suppression with an improved safety profile, ensuring effective care while minimizing impact on renal and bone health — a critical advancement in long-term hepatitis B management.
Built on a foundation of clinical excellence, innovation, and patient-centered care, Tafhep 25 is set to redefine the standard of treatment for chronic hepatitis B.
🔹 About Tafhep 25
- Active Ingredient: Tenofovir Alafenamide 25 mg
- Therapeutic Class: Antiviral Agent, Nucleotide Reverse Transcriptase Inhibitor (NRTI)
- Primary Indications:
- Treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.
- Mechanism of Action:
Tenofovir Alafenamide is a prodrug of tenofovir, allowing targeted delivery to hepatocytes, where it inhibits HBV polymerase, preventing viral replication with greater efficacy at a lower systemic exposure compared to earlier agents.
🔹 Key Features & Benefits
✅ Potent Suppression of Hepatitis B Virus
- Achieves strong and sustained reductions in HBV DNA levels.
✅ Improved Safety Profile
- Reduced risk of renal toxicity and bone mineral density loss compared to earlier tenofovir therapies.
✅ Convenient Once-Daily Dosing
- Enhances patient adherence and treatment outcomes.
✅ Clinically Proven Efficacy
- Supported by robust global clinical trials and real-world use.
✅ Protects Liver Function Over Time
- Helps prevent disease progression to cirrhosis and hepatocellular carcinoma.
🔹 Target Audience
🏥 Hospitals, Hepatology Centers, Infectious Disease Clinics
- An essential treatment in comprehensive hepatitis B management programs.
👨⚕️ Hepatologists, Infectious Disease Specialists, Gastroenterologists, Primary Care Physicians
- A reliable and advanced option for specialists managing chronic HBV patients.
🧑🤝🧑 Patients Living with Chronic Hepatitis B
- Offering hope for better long-term health outcomes and improved quality of life.
🔹 Our Commitment
At Green Apple Pharmaceuticals Private Limited, we are committed to delivering excellence in antiviral therapy through scientifically advanced, clinically trusted, and innovative solutions.
Tafhep 25 reflects our unwavering dedication to patient wellbeing, healthcare empowerment, and advancement in hepatitis B care.
Tafhep 25 — Strengthening the Fight Against Chronic Hepatitis B.
📦 Now Available
For detailed prescribing information, clinical study support, or patient counseling resources, please reach out to our medical affairs team or visit Tafhep 25.
